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Gruppo Italiano Trapianti di MidolloA nonmyeloablative conditioning with total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) was
shown to protect against graft-versus-host disease (GVHD). To evaluate the effects of TLI-ATG in a multicen-
ter study, 45 heavily pretreated patients, median age 51, with lymphoid (n5 38) and myeloid (n 5 7) malig-
nancies were enrolled at 9 centers. Twenty-eight patients (62%) received at least 3 lines of treatment before
allografting, and 13 (29%) had refractory/relapsed disease at the time of transplantation. Peripheral blood
hematopoietic cells were from HLA identical sibling (n 5 30), HLA-matched (n 5 9), or 1 antigen HLA-
mismatched (n 5 6) unrelated donors. A cumulative TLI dose of 8 Gy was administered from day 211
through 21 with ATG at the dose of 1.5 mg/kg/day (from day 211 through 27). GVHD prophylaxis con-
sisted of cyclosporine andmycophenolate mofetil. Donor engraftment was reached in 95% of patients. Grade
II to IV acute GVHD (aGVHD) developed in 6 patients (13.3%), and in 2 of these patients, it developed be-
yond day 100. Incidence of chronic GVHD (cGVHD) was 35.8%. One-year nonrelapse mortality was 9.1%.
After a median follow-up of 28 months (range, 3-57 months) from transplantation, median overall survival
was not reached, whereas median event-free survival was 20 months. This multicenter experience confirms
that TLI-ATG protects against GVHD and maintains graft-vs-tumor effects.
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Table 1. Patient Characteristics
No. of patients 45
Median age at transplantation, yr (range) 51 (23-68)
Median follow-up, mo (range) 28 (3-57)
Male/female 30/15
Disease
CLL 13
NHLa 10*
Hodgkin lymphoma 8
AML/RAEB 4
Multiple myeloma 4
Acute lymphoblastic leukemia 3
Myelodysplastic syndrome 3
High-risk/low-risk disease 39/6
Median time from diagnosis to transplantation,
mo (range)
31 (4-146)
Previous lines of treatment
0 1
1 9
2 7
$3 28
Disease status at transplantation
CR 17
PR 15
Refractory of progressive disease 13
HCT comorbidity index
0 29
1-2 9
$3 7
Donor type
Related 30
HLA-matched URD 9
HLA-mismatched URD 6
CLL indicates chronic lymphocytic leukemia; NHL, non-Hodgkin lym-
phoma; AML, acute myeloid leukemia; RAEB, refractory anemia with
excess of blasts; CR, complete remission; PR, partial remission; HCT,
Biol Blood Marrow Transplant 18:1600-1613, 2012 1601Conditioning to Prevent GVHDgraft-versus-host disease (GVHD) and its treatment-
related mortality [2-4]. In particular, the incidence of
grade II to IV acute GVHD (aGVHD) after
nonmyeloablative conditionings ranged from 20% up
to 65% of patients and, in about half of these, its
complications, especially in steroid refractory
GVHD, were fatal [1,2,5-8]. A different clinical
approach that spares the bone marrow (BM) was
proposed in recent years to prevent aGVHD. It
consists of a nonmyeloablative preparatory regimen
based on murine models of BM transplantation that
uses fractionated total lymphoid irradiation (TLI)
and antithymocyte globulin (ATG). In this model,
the combination TLI-ATG alters the host immune
profile to favor regulatory natural killer T (NKT) cells
that suppress GVHD by polarizing conventional T
cells toward secretion of noninflammatory cytokines
and by promoting the expansion of donor CD41
CD251 regulatory T cells [9-13]. This animal model
was first translated into a clinical pilot study on 37
patients [14]. This single-center experience was re-
cently updated on a total of 111 patients [15]. To con-
firm their findings in a multicenter study and to
evaluate which subsets of patients may most benefit
from this approach, we conducted a prospective phase
II clinical trial through the Gruppo Italiano Trapianto
di Midollo Osseo (GITMO; http://ClinicalTrials.gov;
NCT01081405).hematopoietic cell transplantation; URD, unrelated donor.
aHistologies included 5 follicular lymphomas, 2 diffuse large cell lympho-
mas, 1 Burkitt lymphoma, 1 lymphoblastic lymphoma, and 1 lymphocytic
lymphoma.MATERIAL AND METHODS
Patients
Between November 2007 and August 2010, 45
consecutive patients were enrolled at 9 Italian trans-
plantation centers (Table 1). Inclusion criteria
included hematologic malignancies in whom an allo-
graft is warranted, age #70 years, and Karnofsky per-
formance status $60%. Exclusion criteria included
age above 70 years, Karnofsky performance score be-
low 60%, severe abnormal organ function (heart, kid-
ney, lung, and liver), pregnancy, seropositivity for
human immunodeficiency virus, and presence of active
nonhematologic malignancies. Patient comorbidities
were evaluated according to the hematopoietic cell
transplantation (HCT) comorbidity index score [16].
Eligible donors were either related or unrelated
HLA identical donors who accepted to donate
granulocyte-colony stimulating factor mobilized pe-
ripheral blood hematopoietic cells. One antigen
HLA-mismatched donors were allowed. All patients
signed informed consent upon enrollment. The proto-
col was approved by the institutional review boards
of the participating centers in accordance with the
Declaration of Helsinki (http://ClinicalTrials.gov;
NCT01081405).Treatment Plan
TLIwasplannedas follows: awholebodycomputed
tomography scan was obtained for every patient, and
target volumes were outlined in sequential axial com-
puted tomography images. The clinical target volume
corresponded to all lymphatic stations (bilateral neck,
bilateral axillas, mediastinum, paraortic, bilateral
common iliac, external and internal iliac, inguinal
lymph nodes), and spleen. The Waldeyer ring was ex-
cluded in order to reduce potential toxicity. A planning
target volume was then generated adding a 10-mm
isotropic margin. The neck, thoracic, and abdominal
organs at risk were then contoured. TLI was delivered
over 10 fractions for a total dose of 8 Gy, from
day 211 through 21, with a linear accelerator and
6- to 10-MV photons, using a 3D-conformal technique
consisting of 3 sequential individually shaped antero
posterior and postero anterior fields (mantle, upper
part of inverted Y, and lower part of inverted Y). Portal
images were acquired on the first day and then every 3
days. ATG (thymoglobuline, genzyme) was adminis-
tered at the dose of 1.5 mg/kg/day (from day 211
through 27). Primitive hematopoietic stem cell
infusion was scheduled on day 0. Postgrafting
1602 Biol Blood Marrow Transplant 18:1600-1613, 2012G. Messina et al.immunosuppression consisted of oral cyclosporine and
mycophenolate mofetil. Oral cyclosporine was given at
12.5 mg/kg/day from day 23 until day 156, then ta-
pered to day 180 in the absence of GVHD. Doses
were adjusted to maintain blood trough levels of about
500 ng/mL throughout the firstmonthposttransplanta-
tion unless clinical side effects occurred.Oralmycophe-
nolate mofetil was given at 30mg/kg/day divided into 2
doses fromday0until day28or at 45mg/kg/daydivided
into 3 doses from day 0 until day 40 and then tapered
through day 56 in the setting of related and unrelated
donor (URD) transplantation, respectively.
All patients received standard prophylaxis against
viral, bacterial, and fungal infections. Cytomegalovirus
(CMV) reactivation was monitored through levels of
CMV antigenemia and/or serum CMV DNA and
treated with ganciclovir or foscarnet as clinically indi-
cated.
Chimerism Analysis
Chimerism analyses of peripheral blood T cells
and unfractionated marrow were carried out at days
28, 56, 90, 180, and 360 posttransplantation, and
yearly thereafter with fluorescence in situ hybridiza-
tion in sex-mismatched pairs or PCR-based analyses
of polymorphic microsatellite regions in sex-matched
pairs, as previously described [17]. Mixed chimerism
was defined as between 5% and 95% peripheral blood
donor T cells, and full chimerism was defined as
greater than 95% donor T cells. Graft rejection was
defined as donor CD3-positive cells 5% or less at
any of the assessed time points after achieving post-
transplantation donor chimerism.
GVHD and Relapse Risk
The aGVHD was diagnosed according to the re-
cent indications of the National Institute of Health,
which include clinical features as criteria to discrimi-
nate acute from chronic GVHD (cGVHD) and graded
according to common criteria [18-20]. The cGVHD
was graded as previously described [21]. Hematologic
diseases were classified as at low risk of relapse (chronic
myelogenous leukemia in first chronic phase, refrac-
tory anemia with no blast excess, acute myeloid leuke-
mia, and lymphoblastic leukemia in first remission) or
at high risk of relapse (all other diseases) [22]. Disease
relapse or disease progression was defined as recur-
rence of disease after complete remission (CR) and
partial remission (PR) and progression of persistent
disease, respectively. Standard treatment, as per insti-
tutional guidelines of the participating centers, with/
without donor lymphocyte infusions (DLIs) were al-
lowed to treat progression or relapse posttransplanta-
tion. DLIs were administered in the absence of
clinical GVHD manifestation and after a rapid taper
and discontinuation of the immunosuppression.Statistical Analyses
Primary endpoints were overall survival (OS) and
event-free survival (EFS) from transplantation. OS
was defined as the time from transplantation to death
fromany cause. EFSwas defined as the time from trans-
plantation to progression, relapse, or death, whichever
occurred first. Alive patients without progression or re-
lapse were censored at the date of last contact. Survivals
were analyzed by the Cox proportional hazards model,
comparing the 2 arms by theWald test and calculating
95% confidence intervals. Univariate analyses were
performed for the following variables: age (.50 vs
#50 years), gender (male vs female), type of donor
(matched unrelated vs sibling donor), number of previ-
ous chemotherapy lines (.2 vs#2), HCT comorbidity
index score [16] ($1 vs 0), donor chimerism at day190
and1180 (.95%vs#95%), occurrence of aGVHDor
cGVHD (any vs none), and disease status at transplan-
tation (CR 1 PR vs refractory/progressive disease).
Occurrence of aGVHD and cGVHD were treated as
time-dependent variables. Cumulative incidences of
developing aGVHD, cGVHD, nonrelapse mortality
(NRM), and relapse incidence (RI) were determined
using the Fine and Gray competing risk regression
model. Competing events were defined as relapse and
deathwithoutGVHDfor aGVHDandcGVHD,death
without relapse forNRM, and as relapse forRI [23]. Pa-
tient characteristics were tested using the Fisher exact
test for categorical variables and the Mann-Whitney
test for continuous ones. All reported P values were
2-sided at the conventional 5% significance level.
Data were analyzed as of September 2011 by SPSS
19.0.0 (Chicago, IL) and R 2.13.1 software (The
R Foundation for Statistical Computing, Wien-A).RESULTS
Patient Characteristics
Patient characteristics are reported in Table 1. All
patients were ineligible for a myeloablative conven-
tional allograft either because of age or because of
comorbidities. Of the 45 consecutive patients prospec-
tively enrolled, 38 patients (84%) had lymphoid
malignancies, and 7 patients (16%) hadmyeloid malig-
nancies. The vast majority of patients (78%) had ad-
vanced and heavily pretreated diseases. Only 1
patient with transfusion-dependent chronic myeloge-
nous leukemia with no blast excess received an allo-
graft upfront without previous chemotherapy.
Engraftment
Median numbers of CD341 and CD31T cells in-
fused were 6.0  106/kg (range, 1.1-12.9) and 2.5 
108/kg (range, 0.2-4.0) recipient body weight, respec-
tively. Sustained donor chimerism.95%was achieved
in 24% of the evaluated patients (n 5 37) at day 190
Figure 1. Donor chimerism evaluated on bone marrow and on CD31
T cells over time.
Biol Blood Marrow Transplant 18:1600-1613, 2012 1603Conditioning to Prevent GVHDand in 48% at day 1180 (Figure 1). Of the 32 patients
evaluated at 1 year, 79% were full donor chimeras.
Graft rejection occurred in 2 patients, at day 156 in
a patient who underwent transplantation from an
HLA-matched URD and at day 1180 in a patient
who underwent transplantation from an HLA-
matched related donor. There was no difference in
OS and EFS between patients with donor chimerism
.95% and those with a lower chimerism at 3 and 6
months post-transplant (OS: P 5 .2 and .1; EFS P 5
.3 and .3). One patient who underwent transplantation
from a mismatched URD, who experienced an abrupt
decrease of donor CD31T cell chimerism at day160
received off-protocol DLIs followed by grade II
aGVHD.Figure 2. (A) Cumulative incidence of acute grade II-IV graft-vs.-host
disease (solid line) and competing events (dotted line). (B) Cumulative
incidence of chronic graft-vs.-host disease (solid line) and competing
events (dotted line). (C) Cumulative incidence of non relapse mortality
(solid line), and competing events (dotted line).Transplant-Related Toxicity and Mortality
Overall, grade II to IV aGVHD developed in 6 pa-
tients, including grade III GVHD in 3 patients after an
HLA-matched sibling donor transplantation and
grade IV GVHD in a patient after an HLA-matched
URD transplantation. Overall, the cumulative inci-
dence was 13.3% (Figure 2A), 4 of 6 patients (8.9%)
within day 100, given that 2 patients experienced
late-onset (beyond day 1100) aGVHD. At a median
follow-up of 28 months (range, 3-57 months), 50%
of patients with aGVHD died from NRM, vs 12% of
those who did not develop aGVHD (P 5 .018). Pa-
tients with aGVHD did not relapse, whereas 39% of
the patients without aGVHD did. Cumulative inci-
dence of cGVHD was 35.8%, only 1 patient had re-
ceived an allograft from an URD (Figure 2B). RI at 1
year was 7.1% in patients with cGVHD and 33.3%
in patients without (P 5 .048).
At a median follow-up of 28 months (3-57 months)
from transplantation, NRM was 17.2%, and 1-year
NRMwas 9.1% (Figure 2C). Of note, 3 of 7 deaths oc-
curred after the first 12months posttransplantation dueto viral encephalitis, cGVHD-related complications,
and due to diffuse large cell lymphoma in a patient orig-
inally treated for Hodgkin lymphoma. In this patient,
Epstein–Barr virus-associated lymphoma was ruled
out. Other causes of death included aGVHD (n 5 3)
and graft rejection complications (n 5 1) (Table 2).
CMV reactivation occurred in 20 of 45 patients (44%)
Figure 3. (A) Overall survival from transplant (B) Event-free survival
from transplant.
Table 2. Causes of Death
Causes of Death No. of Patients
Graft rejection 1
aGVHD 3
Viral encephalitis 1
Secondary diffuse large cell lymphoma 1
cGVHD 1
Disease relapse or progression 9
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease.
1604 Biol Blood Marrow Transplant 18:1600-1613, 2012G. Messina et al.after a median of 1.2 months (range, 0.2-11.3 months)
from transplantation, whereas only 1 patient experi-
enced Epstein–Barr virus reactivation at day1165.
Response
Only 6 of 45 patients (13%) were at low risk of re-
lapse. Although advanced, disease at the time of trans-
plantation was chemosensitive in 32 of 45 patients
(71%; 17 CR and 15 PR). The overall posttransplanta-
tion response rate was 73%. Ten of 15 patients who
were in PR at transplantation and 5 of 13 of those pa-
tients with relapsed/refractory disease achieved CR,
for an overall CR rate of 64% (29 of 45 patients).
Five of 45 patients (11%) achieved PR: 3 patients
maintained a pretransplantation PR, whereas 2 pa-
tients had relapsed/refractory disease at transplanta-
tion. Only 6 of 29 patients (21%) who achieved
posttransplantation CR eventually relapsed, whereas
disease recurred in 4 of 5 patients (80%) who achieved
PR. Overall, cumulative incidence of relapse/progres-
sion was 27.1% at 1 year and 44.3% at 36 months. Pa-
tients with chronic lymphocytic leukemia (CLL) and
lymphomas mostly benefited from allografting with
a CR rate of 70.9% (22 of 31 patients) posttransplanta-
tion as compared to a CR rate of 50% (7 of 14 patients)
with other diseases.
OS and EFS
At a median follow-up of 28 months (range, 3-57
months) from transplantation, the median OS was
not reached, whereas the median EFS was 20 months
(Figure 3A and B). By univariate analysis, there was
a trend toward a better OS and in those patients who
underwent transplantation from a URD (hazard ratio
[HR], 2.34;P5 .095).The only significant variables as-
sociated with better EFS were disease in CR or PR at
the time of transplantation (HR, 0.41; P 5 .033) and
the development of cGVHD (HR, 0.02; P 5 .031;
Table 3).DISCUSSION
Though transplant-related mortality has drasti-
cally decreased in the past decade due to the develop-
ment of less toxic conditioning regimens and, partly, toimproved supportive care, GVHD and its treatment
remain one of themajor areas where progress is needed
to further improve transplantation clinical outcomes
[24,25]. The clinical use of TLI as an immune-
modulating strategy that altered T cell mediated
immune responses was first reported in patients
treated for Hodgkin lymphoma [26]. Moreover, in
the late 1970s, preclinical models described TLI as
a nonmyeloablative conditioning that altered the
recipient immune system and resulted in long-term
survival after allogeneic BM and skin grafts [27-29].
The immune-modulating effects of TLI, with/without
ATG, aimed at protecting against GVHD and at
favoring transplantation tolerance after allografting
and solid organ transplantations, were studied in sev-
eral preclinical animal models. It was observed that
TLI-ATG modifies the balance of host T cell subsets
favoring regulatory NKT cells, constitutively more re-
sistant to irradiation through the p53/Bcl-2 apoptotic
pathway, over host conventional T cells. The complex
interplay between residual host IL-4 secreting NKT
cells and donor IL-10 secreting CD41CD251
Table 3. Univariate Analyses of Risk Factors in 45 Patients Conditioned with TLI/ATG
Variable
Univariate Analysis
OS EFS
HR (95% CI) P Value HR (95% CI) P Value
Age: >50/<50 yr 2.65 (0.91-7.70) .074 1.58 (0.71-3.50) .264
Sex: male/female 1.18 (0.41-3.40) .760 0.88 (0.39-1.99) .751
Donor: MUD/MRD 2.34 (0.86-6.35) .095 1.82 (0.80-4.14) .156
Previous CT lines: at least 3/0-2 0.72 (0.27-1.94) .517 1.19 (0.51-2.77) .692
HCT-comorbidity index: >1/0 2.27 (0.85-6.10) .103 1.72 (0.77-3.84) .190
Disease status at transplantation: CR-PR/no
response
0.65 (0.24-1.79) .402 0.41 (0.18-0.93) .033
aGVHDa: yes/no 5.02 (0.41-61.24) .207 1.59 (0.22-11.28) .644
cGVHDa: yes/no 0.11 (0.01-5.98) .276 0.02 (0.01-0.69) .031
Day-180 chimerism: at least 95%/<95% 0.31 (0.06-1.54) .151 0.59 (0.21-1.66) .316
TLI indicates total lymphoid irradiation; ATG, antithymocyte globulin; OS, overall survival; EFS, event-free survival; HR, hazard ratio; CI, confidence in-
terval; MUD, matched unrelated donor; MRD, matched related donor; CT, chemotherapy; HCT, hematopoietic cell transplantation; CR, complete re-
mission; PR, partial remission; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
aTreated as a time-dependent variable.
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presses the GVHD capacity of conventional donor T
cells. However, these mechanisms do not prevent di-
rect tumor cell lysis by donor CD81 T cells. Thus,
graft-vs-tumor effects are not abrogated [9-13].
These preclinical findings were adapted to human
HCT by the Stanford group in the attempt to reduce
clinical GVHD and improve long-term survival
[14,15]. The preliminary findings were first reported
on a cohort of 37 patients with lymphoid malignancies
or acute leukemias. Only 2 of 37 patients developed
aGVHD after HCT. Patients with lymphoid
malignancies changed their disease status from PR to
CR after transplantation. Major tumor shrinking was
also observed outside the TLI radiation fields suggest-
ing strong graft-vs-lymphoma effects [14]. In their re-
cently updated and extended single-center experience,
111 patients with lymphoid and myeloid malignancies
underwent transplantations from matched related do-
nors (n 5 61) or URDs (n 5 50) [15]. At the time of
transplantation, most patients were heavily pretreated
and were at high risk of relapse. The probability of
aGVHD (grade II-IV) by day 100 was 2% in related
and 10% in URD transplantations, whereas the cumu-
lative risk of extensive cGVHD at 3 years was 28% and
26%, respectively [15]. After a median follow-up of 665
days, 67 of 111 patients (60.3%) were alive. Overall, the
3-year probability of OS and EFS was 60% and 40%,
respectively [15]. These findings, in a heavily pretreated
patient cohort at high risk of relapse, showed that graft-
vs-tumor effects were maintained.
To our knowledge, the here-reported GITMO
experience is the first sizable multicenter trial that pro-
spectively used the TLI-ATG conditioning. Although
some differences can be observed, overall, our findings
confirm the Stanford experience. Full-donor chime-
rism was slowly achieved if compared with what wasdescribed in other studies in which nonmyeloablative
conditionings were used [8,22,30]. However, only
2 patients eventually rejected their graft and,
importantly, a delayed achievement of full-donor
chimerism did not seem to have an impact on patient
survival (Table 3). This discrepancy may be explained
by the relatively rapid achievement of high donor chi-
merism seen in most of our patients by the third month
post-transplant. The overall cumulative incidence of
aGVHD was 13.3%. However, day-100 aGVHD
was 8.9%, which is in keeping with the Stanford expe-
rience, 2% and 10% in related and URD transplanta-
tions, respectively. Delayed onset of aGVHD has been
described as not infrequent after reduced-intensity
conditionings [2,31]. In light of the occurrence of
aGVHD symptoms beyond day 100, a new
classification has also been proposed by a consensus
panel [19,20]. In our study, delayed aGVHD
occurred in 2 of 6 patients, which may explain the
slightly higher overall incidence as compared with
what was published by the Stanford group in which
only aGVHD by day 100 was reported [15]. Cumula-
tive incidence of cGVHD was 35.8%. Interestingly,
only 1 patient had received an allograft from a URD.
At a median follow-up of 28 months, overall NRM
was 17.1%, whereas 1-year NRM was 9.1%. Poten-
tially curative graft-vs-tumor effects were confirmed.
Most patients in CR or in PR, and some additional pa-
tients with refractory/progressive disease at transplan-
tation, maintained or achieved CR after the allograft
despite the lack of any possible cytoreductive effect
due to the conditioning regimen. In our study, the ef-
ficacy of immune-mediated antitumor activity was
more evident in patients with CLL and lymphomas.
Even though the reduced sample size did not permit
a Cox multivariate analysis, we still observed that
a lower tumor burden (patients in CR or PR;
1606 Biol Blood Marrow Transplant 18:1600-1613, 2012G. Messina et al.Table 3) at the time of transplantation and the devel-
opment of cGVHD were significantly associated
with better EFS by univariate analysis.
The clinical association between GVHD and anti-
tumor effects was initially reported in the early 1980s
[32]. These findings were also reported in several
more recent reports [33-36]. It is interesting to notice
that TLI-ATG seemed to significantly decrease
aGVHD but not cGVHD to the same extent, suggest-
ing both biological and clinical implications. First,
these findings underline thewell-documented different
pathophysiology between aGVHD and cGVHD, and
second, the current difficulty in separating cGVHD
from graft-vs-tumor effects in the clinical setting.
Cumulative incidence of relapse/progression was
27.1% at 1 year and 44.3% at 36 months. Overall, the
risk of relapse or progression after nonmyeloablative
transplantations remains an issue. A combined ap-
proach with a sequential use of an allograft followed
by consolidation/maintenance with monoclonal Abs
or newly developed targeted drugsmay lead tomore cu-
rative strategies. Novel treatment plans may include
posttransplantation targeted therapies with ofatumo-
mab (anti-CD20) for patients with non-Hodgkin
lymphomas and CLL, or brentuximab vedotin (anti-
CD30) for Hodgkin lymphoma, tyrosine kinase inhibi-
tors for Ph1 acute leukemias, and new agents such as
lenalidomide or bortezomib/carfilzomib for multiple
myelomas [37-42].
In conclusion, our multicenter experience con-
firms previous single-center reports. TLI-ATG is pro-
tective against aGVHD and maintains graft-vs-tumor
effects mainly associated with cGVHD. However,
new avenues of research should be sought to reduce
the risk of disease recurrence. Moreover, further stud-
ies should aim at prospectively comparing different
nonmyeloablative conditioning regimens.ACKNOWLEDGMENTS
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